Downloading...
Download

BEAT

Breaking: QUALCOMM ($QCOM) Shares Dip 5% In Premarket tradingShares in Qualcomm fell more than 5% in Thursdays premarket trading as a disappointing forecast for no growth in its patent licensing business overshadowed a higher-than-expected outlook for sales and profits. The shares fell 4.2% in extended trading on Wednesday, having closed up 1.6% on the day in regular hours. Qualcomm stock is up 14.5% this year. Despite the poor results It is pertinent to note that In 2024, QUALCOMM's revenue was $38.96 billion, an increase of 8.77% compared to the previous year's $35.82 billion. Earnings were $10.14 billion, an increase of 40.24%. Analyst Forecast According to 27 analysts, the average rating for QCOM stock is "Buy." The 12-month stock price forecast is $207.25, which is an increase of 17.85% from the latest price. Technical Outlook As of the time of writing, (NASDAQ: NASDAQ:QCOM ) stock is down 5.11% in Thursday's premarket trading with recent trading session closing with a moderate RSI of 66 however there will be an impediment today on the growth of NASDAQ:QCOM as a gap down is inevitable which is a bearish pattern that leads to further dip. In the case of extreme selling pressure, immediate support lies in the 61.8% fib retracement level. A dip to this could set NASDAQ:QCOM on a bullish course as liquidity has being swept on recent dip.
NASDAQ:QCOMLong
by DEXWireNews
SPLK has been beat down and run down SPLK as you can see has been on this downward trend over the past year essentially however this play had great earnings first and foremost, is in the middle of a conversion going from a software company to a SAAS business model and to align their goals made a big change in leadership asking the CEO to step down and remain as an advisor ( meaning he is leaving on great terms ) to remain with the company says a lot and have asked an executive board member to step up and take on the CEO role moving forward to guide the company through this change being that he comes from a company rich in SAAS ( salesforce ) i feel this transition was not only needed but well deserved. However as we see from the price action the price action still is being run down. However lets take a look at earnings you see positive returns and positive returns per share. Aside from that Cathie Wood also reestablished a new position in SPLK which again are all bullish signs. I am bullish on SPLK and think this too will be a great opportunity when it starts to get some love and attention being that the price is way down from ATH's
SLong
by Stock_Hustle21
BEAT- BEAST is about to be unleashed...Positional/swing tradeBEAT is your prototypical aggressive growth stock- Strong future growth potential with good earning and revenue track record ... If you can overlook its debt level. This beast was tamed for a while after its share price skyrocketed from $25 to almost $80 , but it is ready to unleash its fury again. But first, I think the pullback is in the store facing key resistance lvl in confluence with ichi and BB on the weekly timeframe. In addition, short % of float is around 10%. However, it is a bullish sign when price hovers below the key resistance lvl rather than experiencing outright price rejection. My buy zone is between $45 to $55 for the positional trade. The long term trendline and S/R flip below this price range will act as a strong support. Click the like button and follow me if you like my analysis :D
NASDAQ:BEAT
by Libratus
Planning a trade wayyy before it happens.... HERE'S HOWI'm expecting price to return to the long term descending channel as there is a lot of liquidity there for the taking. I expect this to happen via the channel breaking (wiping out stop losses) then price to continue downward. I have a trade idea already generated before price even reaches that destination, so when it does I am fully prepared for any scenario. If you can try and look to the future then you will get a better feel for the markets. I struggled to explain this one, sorry. Happy trading!
Short
by joebrownFX
6
LET THE MARKET SHOW YOU WHERE TO GONotice the 5 touches of previous resistance marked by the blue arrows. This "strong level" entices people to sell and place their stops just above the level. See how price begins to fall from this level marked at the red arrow? This also draws more sellers into the market; people don't want to miss out; then BOOM! Price breaks the level and wipes out everyone who shorted earlier. The banks know people place stops here. It is great liquidity for them to take then drive price further down. Think of it like this, if you could enter above the level with a sell order you are already getting a better entry price. Currently CHF and JPY are strong as they are safe haven currencies, so it is a good time to short commodity currencies against them. I'm in this trade. Results to follow.
by joebrownFX
let's BEAT it..It might be of some concern to shareholders to see the BioTelemetry, Inc. (NASDAQ:BEAT) share price down 15% in the last month. But that doesn't undermine the fantastic longer term performance (measured over five years). Indeed, the share price is up a whopping 538% in that time. So it might be that some shareholders are taking profits after good performance. But the real question is whether the business fundamentals can improve over the long term. Anyone who held for that rewarding ride would probably be keen to talk about it. See our latest analysis for BioTelemetry To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last half decade, BioTelemetry became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains. Since the company was unprofitable five years ago, but not three years ago, it's worth taking a look at the returns in the last three years, too. We can see that the BioTelemetry share price is up 446% in the last three years. During the same period, EPS grew by 68% each year. That makes the EPS growth rather close to the annualized share price gain of 76% over the same period. So you could reasonably conclude that investor sentiment towards the stock has remained pretty steady, over time. Rather, the share price has approximately tracked EPS growth. get free idea bit.ly
NASDAQ:BEATLong
by ShukriMahadi
BEAT will benefit? Encouraging Near-Term Outlook for Medical SecThe Zacks Medical Services industry comprises third-party service providers and caregivers appointed by core healthcare companies for economies of scale. The industry includes pharmacy benefit managers, contract research organizations (CRO), mobile and wireless medical technology companies, third-party testing labs, surgical facility providers and healthcare workforce solutions providers among others. Over the past few years, the healthcare industry has strategically moved from volume to value-based care. This changing pattern of care calls for efficient and better-quality facilities, thus gradually increasing the need to appoint specialized external service providers. In recent times, biotechnology and pharmaceutical companies have often been seen outsourcing clinical development and data solution services to improve quality of medical care at competitive costs. With growing importance of effective healthcare management, the medical service industry has become an integral part of the modern healthcare mechanism. Here are the industry’s three major themes: With a significant reduction in regulatory and tax burden on U.S. healthcare companies, the space is finally making progress in terms of technology adoption. This is creating opportunities for mobile and wireless medical technology companies. This apart, thanks to the specialized skills and advanced techniques of surgical facility providers, treatments are becoming less invasive with shorter recovery times. In the future, concepts like ‘bed less hospitals’ are expected to become popular. Currently, third-party laboratory testing providers and contract research organizations are also experiencing increasing demand, thanks to the growing need for complex tests, services and clinical research. For the conventional biotechnology and pharmaceutical firms, clinical trials account for the majority of their drug development costs. These firms are right now looking to outsource clinical trials to control escalating costs related to therapeutic complexities, regulatory demands, and timelines. Going by a report published in Contract Pharma, outsourcing to CROs is anticipated to witness 7.4% CAGR through 2019, with a market penetration rate of 72% by 2020. Overall, the global market for clinical trial services is forecast to grow 12% year on year to 2021 (The Business Research Company). With rising cognizance about the benefits of specialized medical caregiving, the need for healthcare workforce/staffing service providers has increased significantly. For example, the demand for nurses has increased manifold and is expected to remain high. Going by a study published by Georgetown University, the economy will create 1.6 million job openings for nurses through 2020.
NASDAQ:BEATLong
by ShukriMahadi